Genotype-guided clopidogrel treatment for heart patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot clinical trial aims to evaluate the safety and effectiveness of genotype-guided clopidogrel monotherapy in patients with Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) who have successfully undergone Percutaneous Coronary Intervention (PCI). Participants will receive clopidogrel based on their genetic profile and will be monitored for bleeding and ischemic complications over six months. The study seeks to determine if this approach can reduce ischemic risk while minimizing bleeding compared to traditional dual antiplatelet therapy. The findings will help assess whether genotype-guided treatment can be a viable alternative for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients aged 18 years or older are eligible for inclusion if all of the following criteria are met:

* Clinical diagnosis of NSTE-ACS (i.e. NSTEMI or unstable angina)
* Successful PCI (according to the treating physician) with implantation of new generation drug eluting stents.
* CYP2C19 extensive or ultra-rapid metabolizer

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

* CYP2C19 poor or intermediate metabolizer
* Known allergy or contraindication for aspirin or clopidogrel.
* Concurrent use of oral anticoagulants (e.g. because of atrial fibrillation)
* Ongoing indication for DAPT at admission (e.g. due to recent PCI or ACS)
* High-risk features for PCI including left main disease, chronic total occlusion, bifurcation lesion requiring 2-stent treatment, saphenous or arterial graft lesion, severely calcified lesion requiring the use of the Rotablator system, ≥3 treated vessels, ≥ 3 stents implanted and total stent length \>60 mm
* Recent stroke, transient ischemic attack (TIA) or intracranial bleeding
* Severe hepatic impairment (Child Pugh class C)
* Planned surgical intervention within 6 months of PCI
* Patients requiring staged procedure (to avoid heterogeneity in the duration of pharmacological treatment between index and staged procedures)
* Pregnant or breastfeeding women at time of enrolment
* Participation in another trial with an investigational drug or device

Where it's running

• St. Antonius Hospital
  Nieuwegein, Utrecht, Netherlands Recruiting

Study contacts

• Study coordinator: Jaouad Azzahhafi, MD
• Email: j.azzahhafi@antoniusziekenhuis.nl
• Phone: +31883201321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Common femoral vein-to-artery diameter ratio to detect elevated LVEDP

  Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.

  Recruiting Burapha University · Chon Buri · NCT07866859

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Digital lifestyle platform after rehabilitation to support self-management

  A digital, patient-facing platform is being tested to see if people who recently finished inpatient rehabilitation will use it and benefit from personalized lifestyle guidance at home.

  Recruiting at 2 sites Insel Gruppe AG, University Hospital Bern · Bern, Canton of Bern and 1 other locations · NCT07597031

• AI-driven Medipixel fractional flow reserve to guide PCI

  This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.

  Recruiting at 23 sites Samsung Medical Center · Seoul, Select State and 22 other locations · NCT07329699

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

• AI-assisted interpretation of chest pain CT in the emergency department

  A pragmatic randomized trial tests whether an AI tool (Angiomics) helps emergency physicians interpret coronary CT angiography in adults with acute chest pain.

  Recruiting Yonsei University · Seoul · NCT07235657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.